Buy MOTS-c Peptide | Weight Loss and Metabolism
PotentPeptide
Back to Buy Peptides
Weight Loss & Metabolism

MOTS-c

Mitochondrial open reading frame of the 12S rRNA-c

A mitochondrial-encoded peptide studied in mice for insulin sensitivity and exercise capacity.

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA rather than in the cell nucleus, first described in 2015. Nearly all of its research comes from cell and mouse studies, where it improved insulin sensitivity, limited diet-induced weight gain and raised physical capacity. As of October 2026, no peer-reviewed study has given native MOTS-c to people. The only human trial was of an analog, CB4211: one 4-week study in 20 adults with obesity and fatty liver, after which its developer, CohBar, moved to wind down. MOTS-c isn't approved as a drug anywhere, and this product is sold for research use only.

MOTS-c research artwork
Weight Loss & Metabolism

Read the research profile for mechanisms, citations, and safety context before comparing vendors. View the MOTS-c research profile.

99%+ Purity
COA Included
Same-Day Dispatch

Key Benefits

Prevented diet- and age-related insulin resistance in mice (2015 study)
Reduced diet-induced weight gain in mice (2015 study)
Activates AMPK through the folate cycle, mainly in skeletal muscle (cell and mouse studies)
Raised physical capacity in young, middle-aged and old mice (2021 study)
Exercise raises the body's own MOTS-c in human muscle and blood (2021; no one was given the peptide)
The analog CB4211 lowered liver enzymes vs placebo over 4 weeks, but liver fat fell about as much on placebo (company-reported trial, 2021)
Steadier energy and training endurance reported by some users; others notice nothing
Anti-aging and cognitive benefits appear in vendor copy; we found no human data for either

Mechanism of Action

In the 2015 discovery study (cell culture and mice), MOTS-c slowed the folate cycle and the purine synthesis tied to it, which led to activation of AMPK, the cell's energy sensor. Skeletal muscle appeared to be its main target. Exercise also switches on AMPK, which is why MOTS-c is often called an exercise mimetic. A 2021 mouse study found it also changed the activity of nuclear genes linked to metabolism and helped muscle cells adapt to metabolic stress. In people, exercise raises the body's own MOTS-c levels in muscle and blood, but none of these steps has been measured in anyone given the peptide.

Dosing Guidelines

Typical Dose

10-15 mg/week

Frequency

2-3x per week

Duration

4-8 weeks

Note: No human dose-finding study exists for native MOTS-c. These figures reflect common user reports, such as 5 mg two or three times a week by subcutaneous injection; forum doses run from about 1 mg three times weekly to 5-10 mg daily for short blocks, and users themselves describe the advice as inconsistent. Some users inject about 30 minutes before training, which no study has tested. The analog CB4211 was given at 25 mg daily by subcutaneous injection for 4 weeks in adults with obesity and fatty liver, but it isn't the same molecule. As of October 2026, WADA prohibits MOTS-c at all times (S4.4.1).

Research & Studies

What mouse studies and the CB4211 analog trial show about MOTS-c, and how users report dosing it.

Read Full Research

How MOTS-c is thought to affect glucose and fat metabolism, based mostly on cell and mouse studies.

Read Full Research

How mitochondrial peptides are being studied for energy metabolism and aging, from mouse work on MOTS-c to the approved drug elamipretide (SS-31).

Read Full Research

Potential Side Effects

Reported side effects may include:

  • - Injection-site reactions, often stinging, itchy welts or hard lumps that can last days (common in user reports)
  • - Mild-to-moderate injection-site reactions were the only common side effect of the analog CB4211 (4-week trial)
  • - Allergic-type reactions, including a few secondhand forum reports of tongue or throat swelling (unverified)
  • - Flushing and headache (vendor lists; not traced to a study)
  • - No human safety data for native MOTS-c; the CB4211 trial (20 adults, 4 weeks) was too small for safety conclusions

This information is for research purposes only. Always consult with a healthcare professional.

Popular Stacking Options

MOTS-c + Semaglutide

Some users take MOTS-c alongside GLP-1 drugs such as semaglutide, hoping to keep energy and training up while losing weight. No study has tested the combination, and MOTS-c has no human weight-loss data. Semaglutide is an FDA-approved prescription medicine (Ozempic, Wegovy); research-use versions aren't equivalent to it.

Shop this stack

MOTS-c + CJC-1295 / Ipamorelin

Some users pair MOTS-c with growth hormone secretagogues, since they act on different systems (AMPK signaling in muscle vs growth hormone release from the pituitary). No study has tested the combination, and as of October 2026 none of the three is approved as a drug anywhere.

Shop this stack

MOTS-c + BPC-157

Users sometimes add BPC-157 for injury recovery. Its tissue-repair data come mostly from rodent studies, and no study has tested it with MOTS-c.

Shop this stack

Frequently Asked Questions

What does taking MOTS-c feel like?

No study has measured this, because no published trial has given native MOTS-c to people. On peptide forums, users most often describe a subtle, steady lift in energy and training endurance without jitters, while some notice nothing after several weeks. The most consistent report is an injection-site reaction: stinging, itching, and red raised welts or hard lumps that can last for days, which some users say is worse at higher doses. A few secondhand forum reports describe allergic-type reactions such as tongue or throat swelling. These are unverified, but a reaction beyond the injection site is a reason to get medical help.

Is MOTS-c for weight loss or athletic performance?

It has been studied for both, but only in animals. In mice, MOTS-c reduced diet-induced weight gain and insulin resistance (2015) and raised physical capacity at several ages (2021). The closest human data come from the analog CB4211: over 4 weeks it lowered liver enzymes and blood glucose slightly more than placebo, with only a trend toward lower body weight, and liver fat fell about as much on placebo. User reports of fat loss are hard to read, because many users take MOTS-c alongside GLP-1 drugs that cause weight loss on their own. For tested athletes, WADA prohibits MOTS-c at all times as of October 2026 (S4.4.1).

How is MOTS-c different from something like Semaglutide?

Semaglutide is a GLP-1 receptor agonist and an FDA-approved prescription medicine for type 2 diabetes and weight management. It lowers appetite, and in the STEP 1 trial adults lost about 15% of body weight at 2.4 mg weekly. MOTS-c is thought to act inside cells, mainly skeletal muscle in mouse studies, through the folate cycle and AMPK, and it has no human weight-loss data. Some users combine the two, but no study has tested that, and research-use semaglutide isn't equivalent to the approved medicine. Talk to a healthcare professional about any prescription weight-loss treatment.

How long does it take to see results from MOTS-c?

There's no tested timeline. No published study has given native MOTS-c to people, and the 4-week CB4211 analog trial measured liver enzymes, glucose and liver fat, not energy or performance. On forums, some users describe more energy within a week or two, while others report nothing after 4-6 weeks; the 4-8 week duration on this page comes from community practice, not a study. Placebo effects, other compounds taken at the same time and variable gray-market product quality all make these reports hard to judge.

More from this category

Compare nearby options in the same category before choosing a research product.

Weight Loss & Metabolism

AOD-9604

Growth hormone fragment studied for fat metabolism

Weight Loss & Metabolism

Cagrilintide

A long-acting amylin analogue studied for appetite reduction and weight loss

Weight Loss & Metabolism

Retatrutide

An investigational triple agonist (GIP, GLP-1 and glucagon receptors) studied for weight loss and metabolic health

Weight Loss & Metabolism

Semaglutide

A GLP-1 receptor agonist studied for weight management and type 2 diabetes

You might also like

These peptides share research keywords or protocol overlap with MOTS-c.

Growth Hormone Secretagogue

CJC-1295

A long-acting GHRH analogue studied in small 2006 human trials for raising growth hormone and IGF-1.

Anti-Aging & Skin Health

SS-31

A mitochondria-targeting peptide studied in rare mitochondrial disease; approved as Forzinity for Barth syndrome only.

Ready to Purchase MOTS-c?

Get pharmaceutical-grade MOTS-c from Simple Peptide with 99%+ purity, third-party lab testing, and same-day dispatch.

Buy MOTS-c Now